Stealth BioTherapeutics has been granted a patent for compositions and methods involving aromatic-cationic peptides, specifically targeting mitochondrial antioxidants. The key claim includes a peptide with the amino acid sequence D-Arg-4-methoxy-2,6-dimethyltyrosine-Lys-Phe-NH2, or its pharmaceutically acceptable salt. GlobalData’s report on Stealth BioTherapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Stealth BioTherapeutics, was a key innovation area identified from patents. Stealth BioTherapeutics's grant share as of July 2024 was 22%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent US12065511B2 introduces an aromatic-cationic peptide characterized by the specific amino acid sequence D-Arg-4-methoxy-2,6-dimethyltyrosine-Lys-Phe-NH2, along with its pharmaceutically acceptable salts. The patent claims a pharmaceutical composition that includes this peptide, potentially combined with a suitable carrier to enhance its delivery and efficacy. This composition is designed for therapeutic applications, particularly in the context of mitochondrial health and oxidative stress.
Additionally, the patent outlines several methods for utilizing the aromatic-cationic peptide. These methods include reducing the number of mitochondria undergoing mitochondrial permeability transition (MPT), preventing MPT, and reducing oxidative damage in mammals. Furthermore, the peptide is proposed to increase the rate of ATP synthesis in mammals, indicating its potential role in energy metabolism. The claims suggest that the peptide could be beneficial for mammals experiencing conditions that necessitate improved mitochondrial function and reduced oxidative stress.
To know more about GlobalData’s detailed insights on Stealth BioTherapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
